

Learn about an Innovative Treatment for Moderate to Severe Dyspareunia (Painful Sex) Due to Menopause

There are an estimated **64 million** postmenopausal women in the United States. As many as **half of them** may suffer from symptoms of Vulvar and Vaginal Atrophy (VVA), including dyspareunia.¹ This program provides insights on treating this underserved patient population.

Saturday, June 22, 2019

11:45am - 1:00pm

Lunch served from 11:45am-12:00pm

Presentation 12:00pm - 1:00pm

Sagamore Ballroom 2

Indiana Convention Center



SUSAN KELLOGG SPADT

PHD, CRNP, IF, FCST

Director of Female Sexual Medicine

Center for Pelvic Medicine, Bryn Mawr, PA

Professor

Drexel University College of Medicine, Philadelphia, PA

The speaker is contracted to speak on behalf of AMAG Pharmaceuticals, Inc.

1. Wysocki S, et al. Clin Med Insights Reprod Health. 2014;8:23-30.

This presentation is sponsored by AMAG Pharmaceuticals, Inc. In accordance with state regulations, healthcare professionals licensed in CA, MA, MN or VT may be subject to restrictions on the acceptance of food or beverages. AMAG will report and publicly disclose the costs associated with any meal provided to healthcare professionals as required by the applicable federal and state laws.

